{"url_path":"/sec/imnn/8-k/2026-06-30/item-5-02","section_key":"item-5-02","section_title":"Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-30","source_url":"https://www.sec.gov/Archives/edgar/data/749647/0001493152-26-031292-index.html","accession_number":"0001493152-26-031292","cik":"0000749647","ticker":"IMNN","issuer_name":"Imunon, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/749647/0001493152-26-031292-index.html","primary_entity_key":"0000749647","primary_entity_name":"Imunon, Inc."},"word_count":540,"has_tables":true,"body_markdown":"** **\n\n \n\n \n\n** **\n\n**Item\n5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of\nCertain Officers.**\n\n \n\n**Retirement\nof interim Chief Financial Officer**\n\n** **\n\nOn\nJune 29, 2026, Jeffrey Church informed Imunon, Inc. (the “Company”) of his intent to retire from the position of interim\nChief Financial Officer (a position he has held since January of 2026), effective July 1, 2026 (the “Retirement Date”). To\nhelp ensure a smooth transition of his responsibilities to his successor, Mr. Church and the Company agreed that he will continue in\na consulting role with the Company. The Company and Mr. Church amended the Consulting Agreement, effective July 1, 2026, pursuant to\nwhich, the Company agreed to pay Mr. Church a monthly retainer of $10,000 (that may be terminated upon 2 business days’\nnotice). Mr. Church’s departure is due to retirement and is without any disagreements with management.\n\n \n\n**Appointment\nof New Chief Financial Officer**\n\n \n\nAs\na result of Mr. Church’s retirement, effective July 1, 2026, the Company appointed Josh Blacher to serve as the Company’s\nnew interim Chief Financial Officer under a master services agreement (the “Agreement”), dated June 24, 2026, between the\nCompany and Danforth Health, Inc., a financial advisory services firm (“Danforth”). Mr. Blacher will serve as the Company’s\nprincipal financial officer and principal accounting officer.\n\n \n\nMr.\nBlacher, age 54, currently serves as an employee of Danforth since September 2022, where he has worked as a chief financial officer in\na consulting capacity for a number of life sciences companies as well as Managing Partner of Columbus Circle Capital LLC since August\n2019. In his capacity as a consultant of Danforth, he has served as Chief Financial Officer of BullFrog AI Holdings, Inc. (Nasdaq: BFRG)\nsince December 2024, among others. During his tenure at Columbus Circle Capital, Mr. Blacher has served as chief financial officer at\nseveral public and private companies. Prior to his tenure at Columbus Circle Capital, Mr. Blacher served as Chief Business Officer at\nInmed Pharmaceuticals (Nasdaq: INM) from April 2018 to August 2019, as Chief Financial Officer of Therapix Biosciences (Nasdaq: TRPX)\nfrom April 2017 to April 2018, and as Chief Financial Officer at Galmed Pharmaceuticals (Nasdaq: GLMD) from October 2014 to March 2017.\nEarlier in his career, Mr. Blacher served in senior capacities at Teva Pharmaceuticals, Deutsche Asset Management and Morgan Stanley.\nMr. Blacher holds a Bachelor of Arts in Economics from Yeshiva University and a Master of Business Administration in Finance from Columbia\nBusiness School.\n\n \n\nUnder\nthe Agreement, the Company will pay Danforth $475 per hour for Mr. Blacher’s service as the Company’s Chief Financial Officer.\nThe foregoing description of the Agreement is not complete and is qualified in its entirety by reference to the Agreement, which is filed\nherewith as Exhibit 10.1 and incorporated by reference herein.\n\n \n\nThe\nselection of Mr. Blacher to serve as principal financial officer and principal accounting officer was not pursuant to any arrangement\nor understanding between him and any other person. Mr. Blacher has no family relationship with any director or executive officer of the\nCompany, and he has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation\nS-K of the Securities Exchange Act of 1934, as amended."}